PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.

Slides:



Advertisements
Similar presentations
Change in longest diameter = -19%. Change in sum of perpendicular diameters = -21%
Advertisements

CLINICAL USE OF SPECT-CT IN BREAST & PROSTATE CANCERS
Yasir Rudha, MD; Amr Aref, MD; Paul Chuba, MD; Kevin O’Brien, MD
Radiologic Imaging Defines the local extent of a tumor Can be used to stage malignant disease Aids in the diagnosis Monitoring tumor changes after treatment.
STAGING OF BRONCHOGENIC CA NSCLC STAGING TNM CLASSFICATION Adenocarcinoma Squamous cell carcinoma Large cell carcinoma T – Primary tumor N – Regional.
Diagnosis.
PET/CT in Oncology George Segall, M.D. Stanford University.
The Thyroid Incidentaloma
18F- FDG PET/CT in the Diagnosis of Tumor Thrombosis
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
Total Lesion Glycolysis by 18 F-FDG PET/CT a Reliable Predictor of Prognosis in Soft Tissue Sarcoma Ilkyu Han Musculoskeletal Tumor Center, Seoul National.
Brain Scan Imaging MRI, CAT, PET Imaging Interpreting Functions of the Brain through Imaging – Activity Case Study – Professional Sports and Head Trauma.
JHSGR 16 th April 2011 Dr Lee Man Kit Derek.  The value of PET in staging adenocarcinoma (e.g. colorectal cancer) is well established Tomoharu T. et.
Application of Positron Emission Tomography ( PET ) in Colorectal Cancer Dr Chan Wai Keung Department of Surgery Ruttonjee and Tang Shiu Kin Hospitals.
By Denae Bush.   1.The disease caused by an uncontrolled division of abnormal cells in a part of the body.  2.A malignant growth or tumor resulting.
AN INTRODUCTION TO PET-CT SCANNING Ray Murphy Chair – MCCN Partnership Group.
Positron Emission Tomography (PET) Scans in Ovarian Cancer Effectiveness of PET Scans and Recommendations for CMS August 20, 2008 Ovarian Cancer National.
CT Scans Advances in Technology help cure cancer. By: Kristin Day.
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Breast Cancer Early detection of disease Precise Staging.
Eleni Galani Medical Oncologist
Steven M. Larson, M.D. Memorial Sloan Kettering Cancer Center
18 F-FET PET Compared with 18 F- FDG PET and CT in Patients with Head and Neck Cancer Present by Intern 羅穎駿 Journal of Nuclear Medicine Vol. 47 No
Update on 18 F-Fluorodeoxyglucose/Positron Emission Tomography and Positron Emission Tomography/ Computed Tomography Imaging of Squamous Head and Neck.
Mirada Casebook Case study 1: Colorectal. Indication: T3 N1 R0 sigmoid colectomy August 2009 CT demonstrated solitary segment VI/VII liver metastasis.
Advances in Nuclear Medicine and its Impact on Diagnosis and Management of GI Cancers Medhat Osman, MD PhD Philip Alderson, MD.
© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Colorectal Cancer Early detection of disease Precise Staging.
How to manage suspected cancer
Integrated PET/CT in Differentiated Thyroid Cancer: Diagnostic Accuracy and Impact on Patient Management J Nucl Med 2006; 47:616–624 報告者 : 蘇惠怡.
The Detection of Bone Metastases in Patients with High-Risk Prostate Cancer: 99 mTc-MDP Planar Bone Scintigraphy, Single- and Multi-Field-of-View SPECT,
Dual-time point 18F-FDG PET/CT scan: is it always working?
PET Applications in Oncology
WORK UPS. Ultrasound method of choice for the differentiation of cysts from solid masses and for guidance in interventional procedures. Benign: – solid.
Diagnosis and treatment of neuroendocrine tumors Dan Granberg.
Functional Imaging with PET for Sarcoma Rodney Hicks, MD, FRACP Director, Centre for Molecular Imaging Guy Toner, MD, FRACP Director, Medical Oncology.
radio-iodinated metaiodobenzylguanidine (123I-MIBG)
Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.
Neck Cancer Head and STATEMENTS ON January 28, 2006 Frankfurt am Main, Germany Surgery Management of Lymph Node Metastases.
Follow up in Chest Tumors : Value of integrated PET/CT By : Dr. Heba Nabil, MSc Radiology Specialist at Nasser Institute For Research and Treatment.
Targeting HER2 and Focusing on Patients With Gastric Cancer Jose Maria Vieitez, MD, PhD Assistant Professor of Oncology Department of Medical Oncology.
Prognostic Value of PET Using 18F-FDG in Hodgkin’s Disease for Posttreatment Evaluation J Nucl Med 2003; 44:1225–1231 Intern 魏敬庭.
FDG PET/CT case report early detection of ovarian cancer NM case conference, chairman: Nan-Jing Peng, MD.
Conflict of Interest Declaration: Nothing to Disclose Presenter: Sophie Lamoureux Title of Presentation: A Comparison of Stereotactic Body Radiotherapy.
Albert J. Chang, MD, PhD 1 Farrokh Dehdashti, MD 2 Perry W. Grigsby, MD, MS 1 Department of Radiation Oncology 1 Department of Radiology and Nuclear Medicine.
LCC COL-1 See Pathologic Stage, Adjuvant Therapy, and Surveillance (LCC COL-3) Φ Φ Φ π π π Colon Cancer.
Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.
간담도 암에서의 PET 의 활용 핵의학과 홍일기. 18 F-FDG PET: Warburg effect.
Date of download: 6/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Diagnostic Accuracy of Colorectal Cancer Staging.
Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor with a complex growth pattern. Imaging plays a crucial role in diagnosis.
University of Pennsylvania Department of Orthopaedic Surgery Joseph King, Eileen Crawford, Abass Alavi, Arthur Staddon, Lee Hartner, Richard Lackman and.
A prospective study of PET/CT in initial staging of small-cell lung cancer : comparison with CT, bone scintigraphy and bone marrow analysis B. M. Fischer1,
Tumor markers 1111.
Melanoma Staging an update
PET Applications in Oncology 2015/2016
CT and PET imaging in non-small cell lung cancer
CORRELATION OF PHYSICAL EVALUATION AND MRI OF CERVICAL LYMPH NODE WITH HISTOPATHOLOGICAL FINDINGS IN ORAL SQUAMOUS CELL CARCINOMA: AN AMBIDIRECTIONAL STUDY.
PET Criteria for Response Assessment After Completion of Therapy for Aggressive NHL and HL Definition of a positive PET scan (Visual assessment is adequate,
Can the American Thyroid Association Risk of Recurrence Predict Radioiodine Refractory Disease in Differentiated Thyroid Cancer Eur Thyroid J 2016;5:
Carcinoma of the Liver By: Renee Alta.
A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.
Role of cytokeratins in the diagnosis and prognosis of the bladder cancer Giorgi Adeishvili MD Multiprofile clinic Consilium Medulla.
Treatment Overview: The Multidisciplinary Team
Pathway for patients with suspected colorectal cancer
Pathway for patients with suspected HPB Cancer Inter Provider Transfer
Using PET in Ovarian Cancer
Cancer 101: A Cancer Education and Training Program for [Target Population] Date Location Presented by: Presenter 1 Presenter 2 1.
Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer?  Kemp H Kernstine, MD, PhD, Kelley A McLaughlin,
Evaluation of Average CT to reduce the artifact in PET/CT
General strategies of Cancer Treatment and evaluation of Response
Serial CT scan images from patient with a partial response.
Figure 12a Pitfalls in N staging at CT and PET
Presentation transcript:

PET in Colorectal Cancer

Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known metastases; evaluate extent or disease or identify other sites of recurrence Evaluate response to chemotherapy

LV 12/09/93 04/23/9608/22/96 PET-FDG SCAN IN RECTAL CA

Coronal MSKCCAL361200

Case 1

Comparison of PET and CT N=40 pts. (93 biopsies) W CT =0.73+/-.06* W PET =0.97/-.02* *P<.001

Biopsy Correlated Finding

Diagnostic Imaging in Oncology Detection Differential Diagnosis Tumor biology relevant to therapy Staging Recurrence Response

PET in Colorectal Cancer PET accuracy between % > CT (75%) Among pt.s with suspected recurrence, SUV > 3.5 has a 90% probability of tumor, and a 10% prob of being a benign lesion Most common reasons for missing lesions is size (< 1 cm in diameter), location (peritoneum), and artifact (lesion near high count area) PET >> CT for Rx response in rectal Ca

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.